

RAPID DOSE THERAPEUTICS CORP.

March 31, 2021

Canadian Securities Exchange
220 Bay Street, 9th Floor
Toronto, Ontario M5J 2W4

Dear Sirs/Mesdames:

**RE: Rapid Dose Therapeutics Corp. (the “Issuer”)
Closing Date – March 19, 2021**

The Issuer acquired all the issued and outstanding shares of 2544737 Ontario Limited, o/a Consolidated Craft Brands, (“**CCB**”) indirectly through a business combination by way of a three-cornered amalgamation between the Issuer, 2814882 Ontario Inc., a wholly-owned subsidiary of the Issuer, (“**Subco**”) and CCB, as contemplated in the amalgamation agreement dated March 7, 2021 (the “**Amalgamation Agreement**”), in accordance with which Subco amalgamated with CCB and the amalgamated corporation became a wholly-owned subsidiary of the Issuer (the “**Transaction**”). In accordance with the terms of the Transaction, the Issuer issued an aggregate of 20,000,000 units (each, a “**Unit**”) at a deemed price of \$0.25 per Unit to the CCB shareholders. Each Unit is comprised of one common share of the Issuer (a “**Common Share**”) and one Common Share purchase warrant (a “**Warrant**”) of the Issuer, each such Warrant entitling the holder thereof to acquire one Common Share at a price of \$0.375 per Common Share at any time on or before March 19, 2023.

Pursuant to section 3.3(a) of CSE Policy 6 - *Distributions*, we confirm hereby that the Issuer acquired indirectly all of the outstanding shares of CCB in exchange for the issuance to the CCB shareholders of an aggregate of 20,000,000 Units.

Yours very truly,

RAPID DOSE THERAPEUTICS CORP.

Per: SIGNED “MARK UPSDELL”
Mark Upsdell, Chief Executive Officer